Journal
CHEST
Volume 125, Issue 2, Pages 617-625Publisher
ELSEVIER
DOI: 10.1378/chest.125.2.617
Keywords
hypersensitivity pneumonitis; idiopathic pulmonary fibrosis; interstitial lung disease; surfactant; surfactant protein-A
Categories
Funding
- NHLBI NIH HHS [HL 54683] Funding Source: Medline
Ask authors/readers for more resources
Study objectives: To measure surfactant protein-A (SP-A) in the BAL of patients with idiopathic pulmonary fibrosis (IPF). Design: We examined SP-A in BAL and lung tissue of patients with IPF who met the stricter recommended criteria for IPF at the time of diagnosis and prior to the beginning of treatment. Patients: Twenty-six patients with IPF confirmed at biopsy and 22 patients with hypersensitivity pneumonitis (HP) were compared with 9 normal volunteers. Interventions: All patients were subjected to pulmonary function testing, BAL, and lung biopsy prior to the beginning of treatment. Measurements and results: We measured SP-A in BAL fluids and performed SP-A immunohistochemistry on lung specimens. Lung tissues of patients with IPF showed extensive type II cell hyperplasia, usually containing greatly increased levels of immunoreactive SP-A. By enzyme-linked immunosorbent assay, we found a twofold increase over normal values in BAL SP-A without changes in total phospholipids. These data were in agreement with semiquantitative assessments of SP-A by protein immunoblotting and by Western blotting of sodium dodecyl sulfate gels. Patients with HP exhibited a threefold increase of BAL SP-A. Conclusions: The reasons for the difference between our results and previously published reports describing decreased SP-A levels in OF is not clear. It may relate to the stricter criteria for diagnosis, the absence of treatment prior to BAL, differences in the patient population, or to other methodologic differences.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available